Do HGH supplements work, and how do they compare with growth hormone peptides and prescription HGH?

The short answer

Evidence tier: 2 — the summary draws on randomized trials of secretagogues and somatropin, plus small crossover studies of supplement ingredients.

Over-the-counter "HGH supplements" do not contain human growth hormone, and the best evidence shows only brief, small rises in GH from ingredients such as arginine and GABA. Growth hormone secretagogue peptides such as MK-677 and tesamorelin raise GH and IGF-1 more reliably, but only tesamorelin is approved, for a narrow use. Real HGH (somatropin) is a prescription injectable, and even it shows small benefits and frequent side effects in healthy older adults.

The main points:

• Pills and sprays labeled "HGH" are amino acid or herbal blends, sometimes called "releasers".
• A short GH spike is not the same as a lasting change in IGF-1, muscle or fat.
• Secretagogue peptides are a different category, with stronger hormonal effects and real trade-offs.
• Prescription somatropin is regulated for specific conditions; distributing it for anti-aging is illegal in the US.

What is in an "HGH supplement"?

Evidence tier: 5 — editorial description of product categories.

Growth hormone is a protein. Swallowed, it would be digested like any other protein, which is why prescription somatropin is given by injection. Products sold as "HGH supplements" therefore do not contain the hormone. They usually combine amino acids (arginine, ornithine, lysine, glutamine), GABA, alpha-GPC or plant extracts, with claims that they help the body "release" more of its own GH. Products labeled "homeopathic HGH" are, by the rules of homeopathy, diluted to the point where little or nothing remains.

Do OTC HGH supplements raise growth hormone?

Evidence tier: 3 — small randomized crossover studies measuring GH for a few hours; no outcome data.

Some ingredients raise GH briefly. In eight young men, single oral arginine doses of 5 g and 9 g raised GH over the next few hours compared with placebo, while 13 g caused gastrointestinal distress in most participants with no extra GH response (Collier et al., 2005). A follow-up found that taking 7 g of arginine before resistance training blunted the GH rise that exercise alone produced (Collier et al., 2006).

GABA showed a larger acute effect. In 11 resistance-trained men, 3 g of GABA raised peak resting GH by about 400% over 90 minutes compared with placebo (Powers et al., 2008).

The catch is what these studies measured: GH over minutes to hours. GH is released in pulses, and a single pulse says little about IGF-1, body composition or how anyone feels. The studies above did not measure lasting changes in IGF-1, muscle or fat, so percentage claims on supplement labels describe a short-term blood reading, not a result.

A worked example, with round numbers for illustration: if a resting GH reading is 0.5 ng/mL, a "400% increase" can mean a reading of 2 to 2.5 ng/mL for part of an hour. Because resting GH between pulses is low, a large percentage can describe a small absolute change. The arginine result also shows that stacking a "releaser" on top of training is not additive; in that study it lowered the exercise response.

How are GH secretagogue peptides different?

Evidence tier: 2 — randomized controlled trials for MK-677 and tesamorelin; phase 1 data for CJC-1295.

Secretagogues act on the pituitary through the GHRH receptor (sermorelin, CJC-1295, tesamorelin) or the ghrelin receptor (MK-677, ipamorelin). Their effects are larger and longer than those of amino acids.

• MK-677 (ibutamoren): in a two-year randomized trial in 65 adults aged 60–81, 25 mg by mouth daily raised GH and IGF-1 into the young-adult range and increased fat-free mass by 1.1 kg versus a 0.5 kg loss on placebo (Nass et al., 2008). It did not reduce visceral or total fat, did not improve strength or function, raised fasting glucose and reduced insulin sensitivity. Appetite increase, mild leg swelling and muscle pain were the most frequent side effects.
• CJC-1295: in phase 1 trials, a single injection raised GH two- to tenfold for six days or more and IGF-1 1.5- to threefold for 9–11 days (Teichman et al., 2006). There are no long-term outcome trials.
• Tesamorelin: in 412 people with HIV and excess abdominal fat, 2 mg injected daily for 26 weeks reduced visceral fat by 15.2% versus a 5.0% increase on placebo, with IGF-1 up 81% (Falutz et al., 2007). The FDA approved it as Egrifta in 2010 for reducing excess abdominal fat in HIV-associated lipodystrophy; the label states it is not indicated for weight loss and that long-term cardiovascular safety has not been studied (FDA, Egrifta label).
• Sermorelin: formerly FDA-approved as Geref. In 2013 the FDA determined it was not withdrawn from sale for reasons of safety or effectiveness (Federal Register, 2013).

MK-677, CJC-1295 and ipamorelin are not approved medicines, and products sold online as "research peptides" carry quality and legal risks of their own.

What does prescription HGH do in healthy adults?

Evidence tier: 1 — a systematic review of randomized trials and a large factorial RCT.

Even the real hormone disappoints as an anti-aging tool. A systematic review of 18 study populations of healthy older adults found GH lowered fat mass by about 2.1 kg and raised lean mass by about 2.1 kg, with no change in body weight (Liu et al., 2007). People on GH had more swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, and were somewhat more likely to develop diabetes or impaired fasting glucose. The authors concluded GH cannot be recommended as an anti-aging therapy, and noted that its distribution for that purpose is illegal in the US.

A 26-week trial in 131 adults aged 65–88 found similar results: more lean mass, little strength gain, and diabetes or glucose intolerance in 18 GH-treated men versus 7 not given GH (Blackman et al., 2002).

Who is growth hormone treatment for?

Evidence tier: 2 — an Endocrine Society clinical practice guideline based on systematic reviews.

The people who do benefit from somatropin have a diagnosed deficiency, not normal age-related decline. The Endocrine Society's guideline on adult GH deficiency says the diagnosis usually needs confirmation by stimulation testing, unless there is a proven genetic or structural cause dating from childhood (Molitch et al., 2011). In that group, treatment improves body composition, exercise capacity, bone and quality-of-life measures, with the most benefit in severe deficiency, and the guideline judges the risks low.

That is the contrast with the healthy older adults above. The same hormone that helps a deficient pituitary gives modest body-composition changes and more side effects in a normal one. A low-normal IGF-1 on a wellness panel is not, by itself, a diagnosis. Our guide to age-related GH decline covers what testing involves.

Who should be most careful with GH-raising products?

Evidence tier: 2 — glucose and side-effect findings from randomized trials and the FDA label.

Raising GH and IGF-1 has predictable effects, and some groups carry more risk:

• People with diabetes or prediabetes. MK-677 raised fasting glucose and reduced insulin sensitivity in its two-year trial. In tesamorelin's phase 3 trials, 4.5% of treated patients developed an HbA1c of 6.5% or higher versus 1.3% on placebo, and the label advises checking glucose before and during treatment, plus retinopathy monitoring in people with diabetes (FDA, Egrifta label).
• Older adults. Swelling, joint pain and carpal tunnel symptoms were more common with GH in the trials of healthy older people. See our article on fluid retention and carpal tunnel with GH peptides.
• Anyone on glucose-lowering medicines. Because these products push glucose up, they can work against diabetes treatment. This is a conversation to have with the prescriber.
• Competitive athletes. GH, GHRH analogues and GH secretagogues are prohibited in sport under anti-doping rules.

What are the red flags when buying?

Evidence tier: 5 — editorial checklist drawn from the evidence above.

• "Contains HGH" on a pill, powder or spray. It cannot, in any useful sense.
• Homeopathic dilution codes such as "30C" next to "HGH". At that dilution, no molecule of the starting substance is expected to remain.
• Large percentage claims ("raises HGH by 600%") without saying what was measured, for how long, and in whom.
• Promises of muscle, fat loss or reversed aging from an amino acid blend.
• "Proprietary blend" with no amount per ingredient, which makes it impossible to compare with the doses used in studies.
• Secretagogues sold as supplements or "not for human consumption", with no certificate of analysis. A real certificate names the batch, the testing lab, the method (usually HPLC and mass spectrometry) and the date, and the batch number should match the vial. Our guides on reading a peptide COA and verifying a vendor go through the checks.
• Anyone offering somatropin without a diagnosis, testing and follow-up.

Limitations

This is an educational overview, not medical advice.

• We read abstracts, not full texts, and did not review every commercial "HGH" formula.
• OTC studies are small (8–11 participants) and mostly in young men.
• Secretagogue trials were done in specific populations, such as older adults or people with HIV, and may not apply to others.
• Regulatory status differs between countries; check the rules where you live.

The bottom line

"HGH supplements" are amino acid and herbal blends that, at best, cause a short GH pulse with no shown effect on body composition. Secretagogue peptides raise GH and IGF-1 in a measurable way, but come with metabolic side effects and, apart from tesamorelin, no approval. Prescription GH works on body composition but has not earned a place as an anti-aging therapy in healthy people. Any decision to change your growth hormone axis belongs in a conversation with a physician, with lab testing before and during.

Related on this site

• Age-related GH decline: what interventions show
• MK-677 (ibutamoren) in 2026
• CJC-1295 and ipamorelin side effects
• Tesamorelin: Egrifta and off-label use
• GH peptides for muscle: the honest evidence
• CJC-1295 vs sermorelin
• Research-grade vs pharmaceutical-grade peptides
• Growth hormone pillar

References

• Collier SR, Casey DP, Kanaley JA. 2005. Growth hormone responses to varying doses of oral arginine. Growth Horm IGF Res. PMID 15809017
• Collier SR, Collins E, Kanaley JA. 2006. Oral arginine attenuates the growth hormone response to resistance exercise. J Appl Physiol. PMID 16741262
• Powers ME, Yarrow JF, McCoy SC, et al. 2008. Growth hormone isoform responses to GABA ingestion at rest and after exercise. Med Sci Sports Exerc. PMID 18091016
• Nass R, Pezzoli SS, Oliveri MC, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. PMID 18981485
• Teichman SL, Neale A, Lawrence B, et al. 2006. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID 16352683
• Falutz J, Allas S, Blot K, et al. 2007. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PMID 18057338
• Liu H, Bravata DM, Olkin I, et al. 2007. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. PMID 17227934
• Blackman MR, Sorkin JD, Münzer T, et al. 2002. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. PMID 12425705
• Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. 2011. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. PMID 21602453
• U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) prescribing information, NDA 022505 (revised label, 2012; initial US approval 2010). accessdata.fda.gov
• U.S. Food and Drug Administration. 2013 (March 4). Notice on GEREF (sermorelin acetate) injection, NDA 19-863 and NDA 20-443: determination that the products were not withdrawn for reasons of safety or effectiveness (Docket FDA-2012-P-1071). Federal Register 78(42). govinfo.gov